Skip to main content
Premium Trial:

Request an Annual Quote

People In The News: Jul 1, 2011

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Beckman Coulter said last week that Peter Dervan, Robert Funari, Van Honeycutt, William Kelley, Susan Salka, Richard Wallace, Lewis Williams, and Betty Woods have delivered their conditional resignations from the company's board of directors, effective as of the appointment time as defined in the company's merger agreement with Danaher.

Danaher completed its $6.8 billion purchase of Beckman Coulter earlier this week. Beckman Coulter is now a part of Danaher's Life Sciences and Diagnostics segment.

Also, Kevin Farr, Charles Haggerty, and Glenn Schafer delivered their conditional resignations from the board, effective as of the effective time as defined in the merger agreement.

Beckman Coulter's board has appointed Daniel Comas, James Ditkoff, Jonathan Graham, Robert Lutz, and Daniel Raskas as directors, effective as of the appointment time. The Danaher designees have not yet been assigned to any committees.


Keith Raffel has joined Complete Genomics as senior vice president and chief commercial officer, effective June 27. He was group vice president,
CRM On Demand Products at Oracle from 2006 to 2008, and group vice president, CRM OnDemand products at Siebel Systems from 2003 to 2006. Raffel founded UpShot, the first cloud-computing company in Silicon Valley, in 1997.

Complete Genomics also said that on June 27, Mark Sutherland became vice president of business development. He had been senior vice president of business development


Steven Salzberg is joining the Johns Hopkins University School of Medicine staff, effective July 1, where he will be a professor of medicine and biostatistics at the McKusick-Nathans Institute of Genetic Medicine. He presently is the Horvitz professor of computer science, and director of the Center for Bioinformatics and Computational Biology at the University of Maryland. Before that, he was senior director of bioinformatics at the Institute for Genomic Research.


Stanley Lapidus has resigned from Helicos BioSciences board. According to a document filed with the US Securities and Exchange Commission, his resignation was not the result of any disagreement with Helicos but the company did not provide a reason. Lapidus stepped down as chairman of Helicos' board in September. His is co-founder of Helicos BioSciences, Cytyc, and Exact Sciences, and is the founder and current president and CEO of SynapDx.


Boreal Genomics appointed Nitin Sood as CEO and a board member. He joins Boreal from Agilent Technologies where he was general manager in charge of the automation business. He previously was a senior manager at Applied Biosystems, now part of Life Technologies.


Peter Allen has joined Oxford Nanopore Technologies as a non-executive board member. Allen was CFO of Abacus Group from 2005 to 2009, and was CFO of Celltech Group from 1992 to 2004. He currently serves on the boards of ProStrakan Group, Chroma Therapeutics, and Proximagen Neuroscience.

Also, Riccardo Pigliucci retired as a board member, having served almost five years.


Spain's Centre for Genomic Regulation named Luis Serrano to replace Miguel Beato as its director. Serrano's initial term will be for five years. Serrano currently heads up the systems biology program at CRG, where he has been deputy director since 2007. Beato was director of CRG for the past 10 years.


Cellectis announced André Choulika, its CEO, has become the French genome engineering firm's chairman. He succeeds Christian Policard, who served as chairman for six years. Policard will stay on as a director. Choulika is the founder of Cellectis and has been its CEO since its founding.


H. Thomas Watkins, president and CEO of Human Genome Sciences was elected new chairman of the board at the Biotechnology Industry Organization. He is one of 18 directors that BIO announced were elected to its board to serve as BIO's executive committee for the 2011-2012 term.

In addition to Watkins, the other directors are: Joshua Boger, at large, founder and member of the board at Vertex Pharmaceuticals; Fabrizio Bonanni, board secretary, executive VP of operations at Amgen; Ian Clark, at large, CEO and head of North American Commercial Operations, Genentech; Ron Cohen, emerging companies section chair, president and CEO of Acorda Therapeutics; Tjerk de Ruiter, industrial and environmental section chair, CEO of Genecor, a division of Danisco; Douglas Doerfler, at large, president and CEO of MaxCyte; Deborah Dunsire, at large, president and CEO of Milennium; Paul Hastings, emerging companies section vice chair, president and CEO of OncoMed Pharmaceuticals; Rachel King, health section vice chair, president and CEO GlycoMimetics; Adam Monroe, industrial and environmental section vice chair, president of Novozymes North America; Richard Pops, at large, chairman, president and CEO of Alkermes; David Pyott, at large, chairman and CEO of Allergan; Stephen Sherwin, board immediate past chair; Jay Siegel, at large, chief biotechnology officer and head of global regulatory affairs, Johnson and Johnson; Mark Skaletsky, board treasurer, chairman of NeuroPhage Pharmaceuticals; Gerald Steiner, food and agriculture section vice chair, executive VP of sustainability and corporate affairs, Monstanto; and Barbara Wells, food and agriculture section chair, president and CEO of ArborGen.

Also, Christopher Rivera has been appointed chairman of the Council of State Bioscience Association, an autonomous council operating within BIO. Rivera is also president of the Washington Biotechnology & Biomedical Association. He replaces Kelly Gilliespie, president of Missouri Biotechnology Association. Rivera was the founder and CEO of Hyperion Therapeutics. Before that he was senior vice president of commercial operations at Tercica.


Brian Ward, a former executive at Genomic Health and Myriad Genetics, was named interim COO at diagnostics firm diaDexus. Ward is currently also a director at the company. Since late 2010, he has been COO at On-Q-ity, and is president of biotechnology consulting firm Advantage Genomics. He served as senior VP of development at Genomic Health from 2007 to 2008. From 1996 to 2006 he held various positions at Myriad Genetics, including most recently senior VP of Medical Operations.


James Collins and Mathukumalli Vidyasagar has joined Selventa as scientific advisors. Collins is a Howard Hughes Medical Institute investigator, William F. Warrant Distinguished professor and professor of biomedical engineering at Boston University. He is a founding core faculty member of the Wyss Institute at Harvard University. Vidyasagar is the Cecil and Ida Green Chair in systems biology science and a professor of bioengineering at the University of Texas at Dallas.


Randy Vader, formerly VP of Quality, Regulatory, and Clinical Affairs for EraGen Biosciences, has launched consulting and contracting firm IVD Consultants, based in Madison, Wis. In 2010 while at EraGen, which was recently acquired by Luminex, Vader worked with the US Food and Drug Administration to get clearance for EraGen's MultiCode-RTx Herpes Simplex Virus 1&2 Kit.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.